BioCryst Pharmaceuticals, Inc.
BCRX
$7.40
$0.182.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -90.94% | -10.72% | 64.18% | 42.69% | -70.77% |
| Total Depreciation and Amortization | 567.20% | -2.81% | 4.58% | -81.28% | 289.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.84% | 6.21% | -2.10% | -9.57% | 3.27% |
| Change in Net Operating Assets | -24.07% | 50.08% | 62.29% | -368.08% | 211.74% |
| Cash from Operations | -163.23% | 702.70% | 97.45% | -501.97% | 55.18% |
| Capital Expenditure | -1,044.07% | 61.94% | 34.04% | 57.58% | 43.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 116.10% | 472.62% | -107.91% | 203.84% | -215.82% |
| Cash from Investing | 109.65% | 446.63% | -108.52% | 200.99% | -223.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 35.97% | -38.31% | -3.08% | 66.52% | -- |
| Issuance of Common Stock | -- | 657.61% | -83.69% | 931.71% | -88.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,081.61% | 85.82% | 21.70% | -8.20% | -729.01% |
| Cash from Financing | -415.62% | 164.80% | -87.60% | 66.97% | -359.02% |
| Foreign Exchange rate Adjustments | -253.23% | 695.10% | 57.94% | -165.13% | 106.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.51% | 418.24% | 77.48% | 34.28% | -951.96% |